Home » Stocks » COLL

Collegium Pharmaceutical, Inc. (COLL)

Stock Price: $24.06 USD 1.77 (7.94%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $24.77 +0.71 (2.95%) Jan 15, 7:05 PM
Market Cap 832.05M
Revenue (ttm) 307.95M
Net Income (ttm) 17.59M
Shares Out 34.54M
EPS (ttm) 0.51
PE Ratio 47.46
Forward PE 5.39
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $24.06
Previous Close $22.29
Change ($) 1.77
Change (%) 7.94%
Day's Open 22.89
Day's Range 22.88 - 24.38
Day's Volume 582,352
52-Week Range 13.89 - 25.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million –

Seeking Alpha - 1 month ago

Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and...

Seeking Alpha - 2 months ago

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...

Zacks Investment Research - 2 months ago

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 2 months ago

These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Other stocks mentioned: ATNX
GlobeNewsWire - 2 months ago

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursda...

The Motley Fool - 3 months ago

These three health-related businesses are well positioned to provide market-beating gains.

Other stocks mentioned: INMD, PFE
GlobeNewsWire - 3 months ago

STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain managem...

GlobeNewsWire - 3 months ago

STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manag...

GlobeNewsWire - 4 months ago

STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain man...

GlobeNewsWire - 4 months ago

STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manag...

Seeking Alpha - 5 months ago

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 5 months ago

– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 –

Zacks Investment Research - 5 months ago

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wedne...

Seeking Alpha - 5 months ago

Collegium Pharmaceuticals - Whether It's Too Cheap

Zacks Investment Research - 6 months ago

AMRX vs. COLL: Which Stock Is the Better Value Option?

Other stocks mentioned: AMRX
Zacks Investment Research - 7 months ago

AMRX vs. COLL: Which Stock Is the Better Value Option?

Other stocks mentioned: AMRX
The Motley Fool - 8 months ago

These are the two healthcare stocks that possess the best value for the greatest reward in May.

Other stocks mentioned: ABBV
Seeking Alpha - 8 months ago

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 8 months ago

A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.

Seeking Alpha - 9 months ago

The Call On Collegium Pharmaceuticals

Zacks Investment Research - 9 months ago

COLL vs. NBIX: Which Stock Is the Better Value Option?

Other stocks mentioned: NBIX
Zacks Investment Research - 10 months ago

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).

Seeking Alpha - 10 months ago

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2....

The Motley Fool - 11 months ago

Investors aren't happy about the drugmaker's proposed senior convertible note offering.

Seeking Alpha - 11 months ago

Collegium Pharmaceutical: 2020 Could Be A Great Year

GlobeNewsWire - 11 months ago

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000...

The Motley Fool - 11 months ago

The speciality pharmaceutical company purchased the full rights to an important drug product.

24/7 Wall Street - 11 months ago

Collegium Pharmaceutical Inc. (NASDAQ: COLL) shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.

GlobeNewsWire - 11 months ago

– Financially Transformative Acquisition –

Zacks Investment Research - 11 months ago

Prospects Appear Bright for Small Drug Industry in 2020

Other stocks mentioned: AMRX, KALV, MTNB
Seeking Alpha - 1 year ago

Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020

Zacks Investment Research - 1 year ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

The Motley Fool - 1 year ago

This biotech stock is promising strong revenue figures and a net profit for 2020.

GlobeNewsWire - 1 year ago

– Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 –

Seeking Alpha - 1 year ago

Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid Lawsuits

GlobeNewsWire - 1 year ago

STOUGHTON, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manage...

The Motley Fool - 1 year ago

Buying proven businesses is better than scouring the pink sheets looking for a viable investment.

Other stocks mentioned: BE, SPWH
Seeking Alpha - 1 year ago

Market Diagnoses Collegium's Opportunity

GlobeNewsWire - 1 year ago

STOUGHTON, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manage...

The Motley Fool - 1 year ago

Investors are excited about the drugmaker's big formulary wins for its abuse-deterrent opioid drug.

Seeking Alpha - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -12.50% and -1.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead...

Zacks Investment Research - 1 year ago

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About COLL

Collegium Pharmaceutical, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 7, 2015
CEO
Joseph Ciaffoni
Employees
255
Stock Exchange
NASDAQ
Ticker Symbol
COLL
Full Company Profile

Financial Performance

In 2019, COLL's revenue was $296.70 million, an increase of 5.81% compared to the previous year's $280.41 million. Losses were -$22.72 million, -41.93% less than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 28.43, which is an increase of 18.16% from the latest price.

Price Target
$28.43
(18.16% upside)
Analyst Consensus: Buy